Switzerland · Delayed Price · Currency is CHF Sandoz Group AG Earnings Call Transcripts
Fiscal Year 2026
-
The session highlighted a strong focus on biosimilars and generics, with robust financials, a leading global pipeline, and major investments in manufacturing and innovation. Strategic launches, regulatory tailwinds, and a shift toward biologics position the company for accelerated growth beyond 2028.
Fiscal Year 2025
-
Net sales grew 5% to $11.1B in 2025, with biosimilars now 30% of sales and core EBITDA margin up to 21.7%. Strong launches, strategic acquisitions, and robust pipeline support mid to high single-digit sales growth in 2026, despite ongoing generics pricing pressures.
-
The session highlighted a conservative approach to GLP-1 expansion, a strong focus on biosimilars with multiple launches, and strategic acquisitions to enhance control and flexibility. Financial guidance remains on track, with operational efficiency and pipeline growth prioritized.
-
Delivered 5% net sales growth and upgraded core EBITDA margin guidance to 21%-22%, driven by strong biosimilar launches and commercial execution. Biosimilars now represent a record 31% of net sales, with further launches and pipeline expansion supporting sustained growth.
-
Delivered strong H1 2025 results with 6% underlying sales growth, 2.5pp EBITDA margin expansion, and biosimilars reaching 30% of Q2 net sales. Confirmed full-year guidance, expanded manufacturing, and announced a $300M biosimilar acquisition.
-
Strong growth in biosimilars and a robust pipeline are driving double-digit sales increases, with a focus on expanding access to affordable medicines globally. Financial performance is solid, with margin expansion, increased dividends, and a strong balance sheet supporting midterm growth targets.
-
Sales surpassed $10 billion with strong biosimilar growth and a strategic shift toward biosimilars. Margin and dividend improvements are on track, with regulatory changes potentially lowering development costs. Regional strength in Europe and new launches, including GLP-1 and denosumab, support midterm growth targets.
-
Q1 delivered 14 consecutive quarters of top-line growth, with biosimilars up 11% and now 27% of sales. Guidance for 2025 is reaffirmed, with mid-single-digit sales growth and a 21% core EBITDA margin expected. U.S. tariffs and price erosion risks are well managed.
-
A leading generics and biosimilars player reported strong sales growth, robust pipeline expansion, and successful product launches in key markets. Operational efficiencies, disciplined investment, and a focus on long-term opportunities like GLP-1s and biosimilars underpin a positive outlook.
Fiscal Year 2024
-
Strong 2024 results with 9% net sales growth, 30% biosimilar expansion, and margin improvement to 20.1%. 2025 guidance targets mid-single-digit sales growth and further margin gains, with biosimilars expected to drive future performance.
-
Sales grew 9% in constant currencies for the first nine months, with Q3 accelerating to 12% growth, driven by biosimilars up 32%. Full-year net sales guidance was raised to high single-digit growth, and EBITDA margin guidance confirmed at around 20%.
-
Strong biosimilar momentum continues, with robust US and ex-US growth, multi-year private label deals, and expanding product launches. Margin improvement is driven by biosimilar mix, higher sales, and cost savings, while GLP-1 and capacity investments position for future opportunities.
-
Management reaffirmed its strategy and midterm ambitions, highlighting strong biosimilar growth, robust pipeline development, and operational improvements targeting a 24%-26% EBITDA margin by 2028. North America and Europe remain key markets, with innovation and partnerships driving long-term value.
-
H1 2024 saw 7% net sales growth, led by a 29% surge in biosimilars, now 27% of total sales. Core EBITDA margin improved sequentially, and full-year guidance was raised to mid- to high-single digit sales growth with a 20% margin target, supported by transformation savings.